Metformin-associated lactic acidosis in a peritoneal dialysis patient.

Abstract

Metformin is one of the commonly used drugs in type-2 diabetes mellitus. It reduces glucose levels by increasing insulin sensitivity, reducing hepatic glucose release and increasing muscle uptake. One of the serious complications associated with metformin use is lactic acidosis, and it is associated with high morbidity and mortality. This is more likely to happen in patients with renal failure due to reduced clearance. International guidelines recommend discontinuing metformin in advanced renal failure. We report a case of metformin-associated lactic acidosis in a patient with end-stage renal disease on peritoneal dialysis. The patient presented with severe lactic acidosis, which was successfully treated with hemodialysis.

• Authors: Najlaa Almaleki, Mohammad Ashraf, Majdi M Hussein, Syed A Mohiuddin
• Journal: Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia (Saudi J Kidney Dis Transpl) Vol. 26 Issue 2 Pg. 325-8 (Mar 2015) ISSN: 1319-2442 [Print] Saudi Arabia
• PMID: 25758883 (Publication Type: Case Reports, Journal Article, Review)

Chemical References

• Hypoglycemic Agents
• Metformin

Topics

• Acidosis, Lactic (chemically induced, diagnosis, therapy)
• Aged, 80 and over
• Diabetes Mellitus, Type 2 (blood, diagnosis, drug therapy)
• Diabetic Nephropathies (blood, diagnosis, therapy)
• Humans
• Hypoglycemic Agents (adverse effects)
• Kidney Failure, Chronic (blood, diagnosis, therapy)
• Male
• Metformin (adverse effects)
• Peritoneal Dialysis (adverse effects)
• Renal Dialysis
• Risk Factors
• Treatment Outcome